Sonoma Pharmaceuticals, Inc. (SNOA) is a global healthcare leader that specializes in identifying, developing, and commercializing innovative, unique therapies for several hard-to-treat inflammatory conditions and infections. The company is headquartered in Petaluma, California, USA, and its operations span various regions globally, including Europe, Latin America, and the Middle East.
Sonoma Pharmaceuticals came into existence in 2009, introducing a wide range of innovative healthcare solutions for medical, dermatology, eye care and animal health. With a strong foundation in oxidative technology, the company has been focusing on treating the chronic inflammatory cells that hallmark diseases like atopic dermatitis, seborrhoeic dermatitis, and itchy or irritated eyes with its increasingly popular hypochlorous acid (HOCl) platform.
Sonoma's product portfolio is primarily based on hypochlorous acid (HOCl), a naturally-occurring molecule with potent antimicrobial properties. Products like Microcyn® Technology have showcased the company’s commitment to bringing innovative, safe, and effective treatments to patients worldwide. Microcyn® is FDA-cleared and significantly improves the outcomes in wound care.
Sonoma Pharmaceuticals is well-regarded for their investment in research and development, resulting in ground-breaking products with far-reaching potential. The company also exhibits a commitment to safety, claiming that Microcyn’s® safety profile is unmatched, offering faster wound healing with a lower risk of infection even when compared to the standard care.
The company trades on the NASDAQ Stock Market under the ticker symbol “SNOA”. Although the company has been faced with a few challenges since inception, it continues to leverage its robust platform, cutting-edge research, and strategic partnerships to help improve patient conditions around the globe. Sonoma Pharmaceuticals, with its strong foundation, unique technology, and emphasis on global health improvement, plays an important role in the healthcare industry.
The team at Sonoma Pharmaceuticals is led by healthcare veterans. Amy Trombly has been the company's CEO since 2022; before that, she held key leadership roles at several esteemed healthcare establishments, showcasing her extensive experience in the industry. Her leadership aims to advance the company’s mission of delivering revolutionary healthcare solutions that transform the lives of patients worldwide.